{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:14:58Z","timestamp":1794366898156,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer-associated fibroblasts (CAFs) play a key role in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). However, the potential mechanisms by which CAFs promote chemotherapy resistance have not yet been explored. In this study, we found that circABCC4 (hsa_circ_0030582) was positively correlated with poor platinum-chemotherapeutic response and a shorter progression-free survival (PFS) time in late-stage PDAC patients. CircABCC4 enhanced the ability of CAFs to induce oxaliplatin resistance in pancreatic cancer cells through glycolysis reprogramming. Mechanistically, circABCC4 enhanced the interaction between PKM2 and KPNA2 to promote PKM2 nuclear translocation in CAFs, leading to the transcription of glycolysis-related genes. The glycolytic reprogramming of CAFs promoted the secretion of IL-8, which in turn enhanced DNA damage repair in pancreatic cancer. Blocking PKM2 nuclear translocation abolished circABCC4-driven oxaliplatin resistance of pancreatic cancer in vivo. Collectively, our study reveals a circRNA-mediated glycolysis reprogramming of CAFs to induce oxaliplatin resistance and highlights circABCC4 as a potential therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-025-07431-4","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T12:23:06Z","timestamp":1740313386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation"],"prefix":"10.1038","volume":"16","author":[{"given":"Rihua","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7422-5222","authenticated-orcid":false,"given":"Rufu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"7431_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cac2.12399","volume":"43","author":"Q Lin","year":"2022","unstructured":"Lin Q, Zheng S, Yu X, Chen M, Zhou Y, Zhou Q, et al. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial. Cancer Commun. 2022;43:257\u201375.","journal-title":"Cancer Commun"},{"key":"7431_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493\u2013502.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7431_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. 2023;29:439\u201353.","journal-title":"Trends Mol Med"},{"key":"7431_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13304-021-01186-1","volume":"74","author":"J Gugenheim","year":"2022","unstructured":"Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022;74:35\u201342.","journal-title":"Updates Surg"},{"key":"7431_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22:213\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"7431_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"key":"7431_CR7","doi-asserted-by":"publisher","first-page":"188997","DOI":"10.1016\/j.bbcan.2023.188997","volume":"1878","author":"Z Li","year":"2023","unstructured":"Li Z, Yin P. Tumor microenvironment diversity and plasticity in cancer multidrug resistance. Biochimica et Biophysica Acta (BBA) - Reviews Cancer. 2023;1878:188997.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"7431_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"7431_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"7431_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322\u201334.","journal-title":"N Engl J Med"},{"key":"7431_CR11","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929\u201339.","journal-title":"J Clin Oncol"},{"key":"7431_CR12","doi-asserted-by":"crossref","unstructured":"Sub\u2013tumor microenvironments influence PDAC progression and therapy response. Cancer Discov. 2021;11:2959.","DOI":"10.1158\/2159-8290.CD-RW2021-151"},{"key":"7431_CR13","first-page":"324","volume":"42","author":"S Zheng","year":"2023","unstructured":"Zheng S, Tian Q, Yuan Y, Sun S, Li T, Xia R, et al. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. JExp ClinCancerRes. 2023;42:324.","journal-title":"JExp ClinCancerRes"},{"key":"7431_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra Y, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023;186:1580\u2013609.","journal-title":"Cell"},{"key":"7431_CR15","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1038\/s41388-022-02253-6","volume":"41","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zheng S, Hu C, Li G, Lin H, Xia R, et al. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene. 2022;41:2372\u201389.","journal-title":"Oncogene"},{"key":"7431_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.23.01771","volume":"42","author":"J St Laurent","year":"2024","unstructured":"St Laurent J, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. JCO. 2024;42:127\u201333.","journal-title":"JCO"},{"key":"7431_CR17","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","volume":"15","author":"MT Broz","year":"2024","unstructured":"Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, et al. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nat Commun. 2024;15:2498.","journal-title":"Nat Commun"},{"key":"7431_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab 2019;30:36\u201350.","journal-title":"Cell Metab"},{"key":"7431_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.","journal-title":"Drug Resist Updat"},{"key":"7431_CR20","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang X, Bai B, Shaha A, He X, He Y, et al. Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis. Hepatology. 2024;80:578\u2013594.","DOI":"10.1097\/HEP.0000000000000763"},{"key":"7431_CR21","doi-asserted-by":"publisher","first-page":"155214","DOI":"10.1016\/j.phymed.2023.155214","volume":"123","author":"X Hu","year":"2024","unstructured":"Hu X, Peng X, Zhang Y, Fan S, Liu X, Song Y, et al. Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect. Phytomedicine. 2024;123:155214.","journal-title":"Phytomedicine"},{"key":"7431_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","volume":"7","author":"B Chen","year":"2022","unstructured":"Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7:121.","journal-title":"Signal Transduct Target Ther"},{"key":"7431_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-023-01452-2","volume":"16","author":"F Zhang","year":"2023","unstructured":"Zhang F, Jiang J, Qian H, Yan Y, Xu W. Exosomal circRNA: emerging insights into cancer progression and clinical application potential. J Hematol Oncol. 2023;16:67.","journal-title":"J Hematol Oncol"},{"key":"7431_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-021-02237-6","volume":"41","author":"S Zheng","year":"2022","unstructured":"Zheng S, Hu C, Lin H, Li G, Xia R, Zhang X, et al. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-\u03baB signaling pathway. J Exp Clin Cancer Res. 2022;41:71.","journal-title":"J Exp Clin Cancer Res"},{"key":"7431_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12943-022-01501-3","volume":"21","author":"C Hu","year":"2022","unstructured":"Hu C, Xia R, Zhang X, Li T, Ye Y, Li G, et al. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF\/STAT3 axis. Mol Cancer. 2022;21:24.","journal-title":"Mol Cancer"},{"key":"7431_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s42003-019-0343-4","volume":"2","author":"T-J Chen","year":"2019","unstructured":"Chen T-J, Wang H-J, Liu J-S, Cheng H-H, Hsu S-C, Wu M-C, et al. Mutations in the PKM2 exon-10 region are associated with reduced allostery and increased nuclear translocation. Commun Biol. 2019;2:105.","journal-title":"Commun Biol"},{"key":"7431_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01096-7","volume":"7","author":"G Zhao","year":"2022","unstructured":"Zhao G, Yuan H, Li Q, Zhang J, Guo Y, Feng T, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. Sig Transduct Target Ther. 2022;7:1\u201315.","journal-title":"Sig Transduct Target Ther"},{"key":"7431_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2016.05.022","volume":"379","author":"J Liu","year":"2016","unstructured":"Liu J, Chen S, Wang W, Ning B-F, Chen F, Shen W, et al. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-\u03b2 pathways. Cancer Letters. 2016;379:49\u201359.","journal-title":"Cancer Letters"},{"key":"7431_CR29","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-10-2828","volume":"71","author":"F V\u00e9gran","year":"2011","unstructured":"V\u00e9gran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-\u03baB\/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71:2550\u201360.","journal-title":"Cancer Res"},{"key":"7431_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer. JAMA Oncol. 2022;8:1571\u20138.","journal-title":"JAMA Oncol"},{"key":"7431_CR31","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.drup.2023.101018","volume":"72","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updat. 2024;72:101018.","journal-title":"Drug Resist Updat"},{"key":"7431_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Annals Oncol. 2023;34:1152\u201364.","journal-title":"Annals Oncol"},{"key":"7431_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/cancers14051231","volume":"14","author":"R-P Czekay","year":"2022","unstructured":"Czekay R-P, Cheon D-J, Samarakoon R, Kutz SM, Higgins PJ. Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets. Cancers (Basel). 2022;14:1231.","journal-title":"Cancers (Basel)"},{"key":"7431_CR34","doi-asserted-by":"publisher","first-page":"188700","DOI":"10.1016\/j.bbcan.2022.188700","volume":"1877","author":"S Sun","year":"2022","unstructured":"Sun S, Yu F, Xu D, Zheng H, Li M. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2022;1877:188700.","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev Cancer"},{"key":"7431_CR35","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-22-3997","volume":"83","author":"Y Kong","year":"2023","unstructured":"Kong Y, Luo Y, Zheng S, Yang J, Zhang D, Zhao Y, et al. Mutant KRAS mediates circARFGEF2 biogenesis to promote lymphatic metastasis of pancreatic ductal adenocarcinoma. Cancer Res. 2023;83:3077\u201394.","journal-title":"Cancer Res"},{"key":"7431_CR36","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1002\/ctm2.1512","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen K, Shou Y, Li S, Wang J, Zhang Q, et al. circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma. Clin Transl Med. 2023;13:e1512.","journal-title":"Clin Transl Med"},{"key":"7431_CR37","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.drup.2023.100960","volume":"68","author":"R Qi","year":"2023","unstructured":"Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat. 2023;68:100960.","journal-title":"Drug Resist Updat"},{"key":"7431_CR38","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-16-1615","volume":"77","author":"L Zhao","year":"2017","unstructured":"Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017;77:1369\u201382.","journal-title":"Cancer Res"},{"key":"7431_CR39","doi-asserted-by":"publisher","first-page":"119421","DOI":"10.1016\/j.biomaterials.2019.119421","volume":"222","author":"M Broekgaarden","year":"2019","unstructured":"Broekgaarden M, Anbil S, Bulin A-L, Obaid G, Mai Z, Baglo Y, et al. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials. 2019;222:119421.","journal-title":"Biomaterials"},{"key":"7431_CR40","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Hayashida T, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, et al. PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer. Cancer Res. 2024;84:1065\u20131083.","DOI":"10.1158\/0008-5472.CAN-23-2266"},{"key":"7431_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41420-021-00804-6","volume":"8","author":"F Wu","year":"2022","unstructured":"Wu F, Wang S, Zeng Q, Liu J, Yang J, Mu J, et al. TGF-\u03b2RII regulates glucose metabolism in oral cancer-associated fibroblasts via promoting PKM2 nuclear translocation. Cell Death Discov. 2022;8:3.","journal-title":"Cell Death Discov"},{"key":"7431_CR42","doi-asserted-by":"publisher","first-page":"121523","DOI":"10.1016\/j.biomaterials.2022.121523","volume":"284","author":"D-Y Hou","year":"2022","unstructured":"Hou D-Y, Xiao W-Y, Wang J-Q, Yaseen M, Wang Z-J, Fei Y, et al. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance. Biomaterials. 2022;284:121523.","journal-title":"Biomaterials"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07431-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T12:23:08Z","timestamp":1740313388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07431-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7431"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07431-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"6 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethical Committee of Guangdong Provincial People\u2019s Hospital. All animal experiments conducted was compliant with the Ethical Committee of Guangdong Provincial People\u2019s Hospital with the protocol number KY2025-031-01. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participat"}}],"article-number":"126"}}